Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting
Chemotherapy is often associated with systemic effects, leading to damage of healthy tissues and organs, the development of drug resistance, immune suppression, and eventually impacting the quality of life of patients. Nanocarriers, small vessels ranging from 1 to 100 nm, can be engineered to effect...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| التنسيق: | article |
| منشور في: |
2025
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://hdl.handle.net/11073/33239 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513431777837056 |
|---|---|
| author | Al-Hajaj, Noura |
| author2 | Khalil, Reem Husseini, Ghaleb |
| author2_role | author author |
| author_facet | Al-Hajaj, Noura Khalil, Reem Husseini, Ghaleb |
| author_role | author |
| dc.creator.none.fl_str_mv | Al-Hajaj, Noura Khalil, Reem Husseini, Ghaleb |
| dc.date.none.fl_str_mv | 2025 2026-03-10T07:25:07Z 2026-03-10T07:25:07Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | Noura Al-Hajaj, Reem Khalil, Ghaleb A. Husseini, Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting, Journal of Drug Delivery Science and Technology, Volume 107, 2025, 106825, ISSN 1773-2247, https://doi.org/10.1016/j.jddst.2025.106825. 1773-2247 https://hdl.handle.net/11073/33239 10.1016/j.jddst.2025.106825 |
| dc.language.none.fl_str_mv | en_US |
| dc.relation.none.fl_str_mv | https://doi.org/10.1016/j.jddst.2025.106825 |
| dc.subject.none.fl_str_mv | Intranasal route Central nervous system (CNS) Blood-brain barrier (BBB) Nanoparticle-based drug delivery |
| dc.title.none.fl_str_mv | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| dc.type.none.fl_str_mv | Peer-Reviewed Published version info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Chemotherapy is often associated with systemic effects, leading to damage of healthy tissues and organs, the development of drug resistance, immune suppression, and eventually impacting the quality of life of patients. Nanocarriers, small vessels ranging from 1 to 100 nm, can be engineered to effectively carry the treatment to the targeted cells or tissues, revolutionizing drug delivery. Nanomedicines have proven to enhance the therapeutic index of drugs by improving the drug's physicochemical properties, such as stability, solubility, and bioavailability, while minimizing toxicity and undesirable side effects. Despite advancement with nanocarriers, targeting the central nervous system (CNS) remains challenging due to the blood-brain barrier, one of medicine's greatest enigmas. The intranasal route offers a direct, non-invasive pathway to the brain, circumventing this barrier that has long hindered CNS treatments. This review aims to present the latest advancements in intranasal nanoparticle-based drug delivery, a method that is poised to revolutionize the treatment of neurological disorders. By exploring the collective efforts to refine this approach, we highlight the main deficiencies found in the literature and discuss how the next generation of lipid-polymer hybrid nanoparticles can transform the future of intranasal targeted drug delivery, enhancing treatment efficacy and patients' quality of life. |
| format | article |
| id | aus_be6fb647029319a9de3c3971c1ee43c4 |
| identifier_str_mv | Noura Al-Hajaj, Reem Khalil, Ghaleb A. Husseini, Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting, Journal of Drug Delivery Science and Technology, Volume 107, 2025, 106825, ISSN 1773-2247, https://doi.org/10.1016/j.jddst.2025.106825. 1773-2247 10.1016/j.jddst.2025.106825 |
| language_invalid_str_mv | en_US |
| network_acronym_str | aus |
| network_name_str | aus |
| oai_identifier_str | oai:repository.aus.edu:11073/33239 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targetingAl-Hajaj, NouraKhalil, ReemHusseini, GhalebIntranasal routeCentral nervous system (CNS)Blood-brain barrier (BBB)Nanoparticle-based drug deliveryChemotherapy is often associated with systemic effects, leading to damage of healthy tissues and organs, the development of drug resistance, immune suppression, and eventually impacting the quality of life of patients. Nanocarriers, small vessels ranging from 1 to 100 nm, can be engineered to effectively carry the treatment to the targeted cells or tissues, revolutionizing drug delivery. Nanomedicines have proven to enhance the therapeutic index of drugs by improving the drug's physicochemical properties, such as stability, solubility, and bioavailability, while minimizing toxicity and undesirable side effects. Despite advancement with nanocarriers, targeting the central nervous system (CNS) remains challenging due to the blood-brain barrier, one of medicine's greatest enigmas. The intranasal route offers a direct, non-invasive pathway to the brain, circumventing this barrier that has long hindered CNS treatments. This review aims to present the latest advancements in intranasal nanoparticle-based drug delivery, a method that is poised to revolutionize the treatment of neurological disorders. By exploring the collective efforts to refine this approach, we highlight the main deficiencies found in the literature and discuss how the next generation of lipid-polymer hybrid nanoparticles can transform the future of intranasal targeted drug delivery, enhancing treatment efficacy and patients' quality of life.2026-03-10T07:25:07Z2026-03-10T07:25:07Z2025Peer-ReviewedPublished versioninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfNoura Al-Hajaj, Reem Khalil, Ghaleb A. Husseini, Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting, Journal of Drug Delivery Science and Technology, Volume 107, 2025, 106825, ISSN 1773-2247, https://doi.org/10.1016/j.jddst.2025.106825.1773-2247https://hdl.handle.net/11073/3323910.1016/j.jddst.2025.106825en_UShttps://doi.org/10.1016/j.jddst.2025.106825oai:repository.aus.edu:11073/332392026-03-11T05:19:34Z |
| spellingShingle | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting Al-Hajaj, Noura Intranasal route Central nervous system (CNS) Blood-brain barrier (BBB) Nanoparticle-based drug delivery |
| status_str | publishedVersion |
| title | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| title_full | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| title_fullStr | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| title_full_unstemmed | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| title_short | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| title_sort | Intranasal drug delivery: Pathways, challenges, and advancements in CNS targeting |
| topic | Intranasal route Central nervous system (CNS) Blood-brain barrier (BBB) Nanoparticle-based drug delivery |
| url | https://hdl.handle.net/11073/33239 |